Sep 13, 2022 / 01:10PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Amgen with us here.
Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So very pleased to have Bob Bradway, the CEO of Amgen. Bob, I know you want to make some opening comments. So I'll turn it over to you, and then we can get going.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Sure. Thank you, Matthew. Thanks for having us again. It's a pleasure to be here in person for a change. Let me just try to remind you what we're doing at Amgen, and I'll start by saying that building on our track record of execution. We're focused on delivering long-term growth, which we define as solid mid-single digits
Amgen Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers